The prevalence and clinical significance of naturally occurring mutations in the full-length surface and overlapping polymerase genes of hepatitis B virus (HBV) were analyzed in 42 patients with chronic hepatitis. Mutations were observed in 10 patients (24%) in the a determinant region, which is the neutralizing epitope within the major hydrophilic region of the surface gene. A high proportion of these mutations (17/18; 94%) occurred in the first loop, unlike mutations induced by immunization. The presence of serum antibody to hepatitis B surface antigen was significantly associated with these mutations. No other region of the surface gene contained any cluster of mutations. These results suggest that escape mutations commonly contribute to persistency in the natural course of HBV infection. In contrast, mutations affecting the major catalytic domains of the polymerase gene, which could alter susceptibility to antiviral nucleoside analogues, were not detected at all.
The prevalence and clinical significance of naturally occurring mutations in the full-length surface and overlapping polymerase genes of hepatitis B virus (HBV) were analyzed in 42 patients with chronic hepatitis. Mutations were observed in 10 patients (24%) in the a determinant region, which is the neutralizing epitope within the major hydrophilic region of the surface gene. A high proportion of these mutations (17/18; 94%) occurred in the first loop, unlike mutations induced by immunization. The presence of serum antibody to hepatitis B surface antigen was significantly associated with these mutations. No other region of the surface gene contained any cluster of mutations. These results suggest that escape mutations commonly contribute to persistency in the natural course of HBV infection. In contrast, mutations affecting the major catalytic domains of the polymerase gene, which could alter susceptibility to antiviral nucleoside analogues, were not detected at all.
Several hundred million people throughout the world are chronically infected with hepatitis B virus (HBV), which eventually leads to life-threatening sequelae such as liver cirrhosis and hepatocellular carcinoma [1] . In general, the coordination of humoral and cellular immune responses to virus-encoded proteins is responsible for virus clearance. In the case of HBV infection, the humoral immune response to HBV surface protein contributes to the clearance of circulating HBV particles, whereas cellular immune responses are responsible for the elimination of infected hepatocytes [2] . Practically, the clearance of HBV occurs only in a small proportion of patients infected at birth, partly because of inadequate humoral and cellular immunity of the host [3] . Alternatively, the emergence of variant viruses that could escape from humoral and cellular immunity may be implicated in persistency, as reported in several other viruses [4, 5] . However, the contribution of immune escape variants in the natural course of HBV infection remains unclear.
The surface gene of HBV contains a dominant neutralizing epitope termed a determinant located within the major hydrophilic region of the surface gene. The production of an antibody to the a determinant after vaccination usually protects against HBV infection. Similarly, in patients with chronic HBV infec-tion, clearance of HBV occurs in association with seroconversion from hepatitis B surface antigen (HBsAg) to the antibody to HBsAg (anti-HBs). Primary prevention of HBV infection, such as vaccination in infants born to HBsAg-positive mothers and immunoprophylaxis in orthotopic liver transplantation recipients, exerts strong selective pressure on HBV, which, in some cases, induces escape mutations within the a determinant region [6] [7] [8] [9] [10] [11] [12] . In these cases, HBV could replicate in the presence of anti-HBs. Similar escape mutations in the a determinant could also arise in the natural course of HBV infection, resulting in active viral replication and liver disease after seroconversion to anti-HBs in patients with chronic hepatitis B [13, 14] . The prevalence of these naturally occurring mutations in the a determinant, however, remains unknown because of the lack of comprehensive studies. The surface gene of HBV also contains putative HLA class I-restricted cytotoxic T lymphocyte (CTL) epitopes [2] . In general, viral mutations in CTL epitopes could evade cellular immunity and thus contribute to persistency [4, 5] . A recent study from Taiwan revealed a high frequency of mutations at amino acid positions 40 and 47 of the surface gene that coincides with the HLA-restricted CTL epitope in patients with chronic hepatitis B, and it was suggested that these mutations might contribute to chronic infection [15] . Because the number of patients analyzed in that study was relatively small, it is not clear whether these amino acid positions universally represent mutation-clustering regions or whether these mutations actually serve as immune escape mutations. Moreover, the frequency of mutations within the other regions of the HBV surface gene has not been studied comprehensively, and the occurrence and clinical significance of the mutations among patients with chronic hepatitis B remain to be established.
The genome of HBV encompasses 4 overlapping open-read-ing frames, and the surface gene overlaps with the catalytic domains of the polymerase gene [16] . Thus, mutations in the surface gene may also affect the polymerase gene, which may alter viral replication. Conversely, mutations in the polymerase gene could have an impact on the surface gene. Recent studies have shown that some specific mutations in the catalytic domains B and C of the polymerase gene, especially in the YMDD motif of domain C, often appear in relation to the breakthrough during antiviral therapy with nucleoside analogues such as lamivudine or famciclovir [17] [18] [19] . Therefore, the susceptibility of surface gene mutants to the antiviral therapy may be altered because mutations in the surface gene may affect these critical regions of the polymerase gene.
The aims of the present study were to elucidate (1) the prevalence of naturally occurring mutations in the surface gene, especially immune escape mutations; (2) their clinical significance in the natural course of HBV infection; and (3) the effect of surface gene mutations on the overlapping polymerase gene.
Materials and Methods
Materials. Sera were obtained from 45 Japanese patients with chronic HBV infection who had been routinely followed up at our hospital. Presence of HBsAg, hepatitis B e antigen (HBeAg), and antibody to HBeAg (anti-HBe) was measured by commercially available EIA (Abbott Laboratories, Abbott Park, IL), and antiHBs was measured by RIA (Abbott). Six of the patients were HBeAg-positive asymptomatic healthy carriers who had no history of liver disease and whose liver function had been persistently normal for у24 months. Thirty-nine were patients with chronic liver disease confirmed by radiologic and/or histologic evidence and had a history of elevated alanine aminotransferase (ALT) levels that had persisted for у6 months, and 37 of the 39 patients actually had elevated ALT levels at the time of serum sampling for the HBV sequence analysis. Sixteen patients were positive for HBeAg, 18 were positive for anti-HBe, and 5 were positive for both HBeAg and anti-HBe. All individuals were positive for HBsAg, and 11 patients were also positive for anti-HBs. No patients had a history of HB vaccination or therapy with hyperimmune globulin or nucleoside analogues. Sera were stored at Ϫ70ЊC until DNA was extracted. Antibodies to hepatitis C virus were measured by the second-generation EIA, and all the patients proved to be negative.
Primer synthesis. Nested primers for polymerase chain reaction (PCR) were synthesized by a DNA synthesizer (model 391; Applied Biosystems Japan, Tokyo) on the basis of the published HBV sequence pNDR260 [20] . Amplification of HBV gene. DNA was extracted from sera by a sodium hydroxide method [21] . Briefly, 10 mL of serum was treated with 0.1 N sodium hydroxide in a volume of 20 mL at 37ЊC for 60 min and then was neutralized with hydrochloric acid. A 2-mL aliquot was amplified by hot-start PCR in a 50-mL mixture with 10 pmol of the outer primer sets for 35 cycles. Each cycle consisted of denaturation at 94ЊC for 15 s, annealing of primers at 55ЊC for 15 s, and extension at 72ЊC for 15 s. Then, second-round PCR was performed on 1mL of the first PCR products in a 50-mL mixture with 10 pmol of the inner primer sets for 35 cycles under the same reaction conditions as the first-round PCR. The second-round PCR products were electrophoresed through agarose gel and visualized under ultraviolet light. Negative controls were included in each PCR round, and false-positive results were cautiously avoided by the strict application of contamination-prevention guidelines [22] .
Direct sequencing of PCR products. Residual dNTPs and primers were removed from the PCR products by using a centrifugation filtration column (Suprec-02; Takara, Kyoto, Japan) and adjusted to a final volume of 50 mL with TRIS-EDTA buffer. Nucleotide sequences of the PCR products were directly determined by using Taq DyeDeoxy Terminator Cycle sequencing kits with an automated DNA sequencer (model 373A; Applied Biosystems Japan). In brief, 7 mL of purified PCR product was mixed with 3.2 pmol of the sequencing primers, 1 mL of each DyeDeoxy Terminator (A, G, C, T), 1 mL of a dNTP mixture (750 mM dITP, 150 mM dATP, 150 mM dTTP, and 150 mM dCTP), 4 U of AmpliTaq DNA polymerase, and 4 mL of the reaction buffer (400 mM Tris-HCl, 10 mM MgCl 2 , and 100 mM [NH 4 ] 2 SO 4 at pH 9.0) in a volume of 20 mL. Cycle sequencing reactions were performed for 25 cycles, each cycle consisting of 96ЊC for 30 s, 50ЊC for 25 s, and 60ЊC for 4 min. An excess of DyeDeoxy Terminators was removed from the completed reaction mixture by using Centri-Sep spin column (Princeton Separations, Adelphia, NJ). Samples were dried in a vacuum centrifuge (TOMY, Tokyo, Japan), dissolved in a loading buffer (5 mL of deionized formamide and 1 mL of 50 mM EDTA at pH 8.0), and loaded onto a DNA sequencer (model 373A; Applied Biosystems Japan) according to the manufacturer's instructions.
Deduced amino acid sequences were compared with the reported consensus sequences of 8 genotype C, subtype adr, HBV clones that were reported in the literature (pAK66, pIWK146, pNDR260 [20] , pSK619 [23] , pYRB259 [24] , pHBV1-1 [25] , pHBr330 [26] , and pBRHBadr4 [27] ). Mutations were defined as sequences that differed from the consensus sequence. The surface and polymerase genes of these clones were relatively conserved, but there were several positions where variations existed: 6 positions in the surface gene (positions 3, 68, 126, 183, 194 , and 224) and 7 positions in the polymerase gene (positions 458, 470, 472, 476, 482, 571, and 572). At these positions, mutations were defined as sequences that differed from all of the 8 clones.
Statistical analysis. Wilcoxon's test was used for the analysis of differences in the frequency of mutations between genomic regions. In the analysis of various clinical factors in relation to the presence of mutations, Fisher's exact test was used for the categorized data, two-tailed Student's t test was used for age and ALT, and the MannWhitney U test was used for HBV-DNA polymerase. In all analyses, was considered significant. Statview-J version 4.5 P ! .05 (Statview; Abacus Concepts, Berkeley, CA) was used for these analyses. Statistic program JMP version 3.1 (SAS Institute, Cary, NC) was used for logistic analyses.
GenBank accession numbers: The nucleotide sequence data reported in this paper will appear in the DDBJ/EMBL/GenBank nucleotide sequence databases with the accession numbers AB029950 to AB029991.
Results
Nucleotide and deduced amino acid sequences encoding the full-length surface region of HBV were determined in 45 pa- Mutations at amino acid residues 40 and 47 that coincided with HLA class I-restricted CTL epitopes were observed in only 1 and 2 patients, respectively, which is in contrast to a recent study that reported frequent mutations at these amino acid residues [15] . The major hydrophilic regions upstream and downstream of the a determinant (amino acids 107-160) were reported to be frequently mutated in patients after therapeutic failure with hyperimmune globulin [28] or in those who were negative for serum HBsAg in spite of HBV viremia [29] . In the present study, however, these regions were also highly conserved. Cysteine residues that are believed to stabilize the conformational structure of the major hydrophilic region were NOTE. HBeAg, hepatitis B e antigen; anti-HBe, antibody to HBeAg; antiHBs, antibody to hepatitis B surface antigen; ALT, alanine aminotransferase. Fisher's exact test was used for the categorized data, two-tailed Student's t test was used for age and ALT, and the Mann-Whitney U test was used for HBV-DNA polymerase. Statview-J, version 4.5 (Abacus Concepts), was used for these analyses.
a Present versus absent (percent).
completely conserved. Positions 122 and 160, which determine the d/y and w/r subtypes of HBsAg, were also completely conserved. The number of mutations per amino acid residue was significantly high in the a determinant region compared with the other regions of the HBV surface genome (range, 0-vs. mutations per site per patient;
Ϫ1 Ϫ1
1.20 ϫ 10 0-0.25 ϫ 10 by Wilcoxon's test; figure 2) . P = .02
Among a total of 18 mutations at 7 amino acid positions in the a determinant, 16 were consistent with the previously characterized escape mutations, and 2 were novel mutations that had not been previously reported (phenylalanine r lysine in position 134 and proline r histidine in position 135). These 2 mutations were observed in a 47-year-old woman (patient 10). Although she was positive for anti-HBs with a relatively high titer (cutoff index of 10.0), she had active liver disease with elevated serum ALT levels (316 IU/mL) accompanied by active replication of HBV (serum HBV-DNA levels of 260 mEq/mL), suggesting that these mutations may be novel escape mutations.
Comparisons of various clinical features in terms of the presence of mutations in the a determinant region are presented in table 1. The presence of anti-HBe and anti-HBs was associated with mutations in the a determinant region (anti-HBe, P = ; anti-HBs, ; Fisher's exact test for both). There was .03 P = .01 no significant association between presence of mutations in the a determinant and the other clinical features, including age, sex, serum ALT levels, and HBV-DNA polymerase levels. A multivariate analysis revealed that the presence of anti-HBs was the only independent factor associated with the a determinant mutations (table 2) .
Because the surface gene overlaps with the major catalytic domains of the polymerase gene, the occurrence of mutations in the polymerase gene was also analyzed (figure 3). As a result, amino acid mutations were observed at 5 positions in 11 patient. Mutations at amino acid positions 403, 423, 471, 482, and 487 were observed in 2 (4.8%), 2 (4.8%), 4 (9.5%), 6 (14.3%), and 8 (19.0%) patients, respectively, and other mutations were present in only 1 patient. The mutation at position 423 that was observed in 2 patients affected the first amino acid position of domain A, but the other catalytic domains of the polymerase gene [30] were highly conserved. A cluster of mutations was observed between amino acids 482 and 487, a region upstream of domain B that overlaps with the a determinant region of the surface gene. The relationships between the mutations in the surface and the polymerase genes are shown in table 3. Amino acid mutations at positions 403 and 482 of the polymerase gene were accompanied by mutations at positions 47 and 126 of the overlapping surface gene, and 3 of 8 amino acid mutations at position 487 of the polymerase gene also altered amino acid 131 of the surface gene. In contrast, amino acid mutations at positions 423 and 471 and 5 amino acid mutations at position 487 were silent for the surface gene. The presence of these mutations was not associated with any clinical features, including age, sex, serum ALT levels, HBV-DNA polymerase, and the presence of HBeAg and anti-HBe or anti-HBs (data not shown). There were no mutations known to be associated with a resistance to lamivudine or famciclovir therapy, such as a methionine r valine or methionine r isoleucine mutation in the YMDD motif of domain C (position 552) or mutations in positions 514, 521, 525, and 528 of domain B [17] [18] [19] .
Discussion
In the present study, mutations in the full-length surface gene were analyzed comprehensively in a natural population of 42 patients chronically infected with a single genotype of HBV. As a result, we observed a cluster of mutations only in the a determinant region, and we determined that the prevalence of these mutations among the studied population was as high as 24%. The calculated number of mutations per amino acid residue was significantly high in the a determinant region compared with the other regions of the HBV surface genome, suggesting the presence of a selective pressure for the mutations in the a determinant. Humoral immune pressures may have selected escape-variant viruses during the course of chronic infection, because the mutations in the a determinant were significantly associated with the presence of serum anti-HBs. This view is also supported by the fact that 16 of the 18 mutations observed in this study were consistent with the previously characterized escape mutations, which could replicate in spite of the presence of anti-HBs [6] [7] [8] [9] [10] [11] [12] [13] [14] [31] [32] [33] [34] . Although the other 2 mutations were novel mutations that had not been reported, they occurred in a single patient who had active liver disease and replication of HBV in spite of the relatively high titer of anti-HBs, suggestive of escape mutations. Thus, the escape phenomenon from the neutralizing anti-HBs could be one of the mechanisms of persistency, even in patients who have not received vaccination or hyperimmune globulin therapy.
In 4 cases, mutations in the a determinant were seen without the presence of anti-HBs. The lack of serum anti-HBs in these patients does not necessarily indicate lack of humoral immune responses to the a determinant, because it has been reported that anti-HBs that is complexed with HBsAg could be detected in nearly all patients with chronic hepatitis B when analyzed by a highly sensitive immunoassay [35] . Therefore, our data suggest that these escape mutations could be induced by an immunological pressure exerted on the a determinant, even in patients who are found to be negative for serum anti-HBs by use of the usual assay. An alternative interpretation may be that these mutations occurred in another individual, and then the mutants were transmitted to these patients.
A recent study on HB hyperimmune globulin therapy failure in liver transplant recipients revealed that therapeutic failure was associated with mutations in the a determinant region in some, but not all, patients. In other patients without a determinant mutations, therapeutic failure was associated with mutations in the major hydrophilic region of the surface gene outside the a determinant (positions 99-169) [28] . Because the exact border of the neutralizing domain is unknown, the authors suggested that these mutations may have contributed to the therapeutic failure. In some patients being studied here, HBV without mutations in the a determinant region replicated actively in the presence of anti-HBs. The major hydrophilic regions other than the a determinant were also highly conserved, suggesting that escape mutations were not involved in these patients. Thus, anti-HBs in these patients may not be directed to the neutralizing epitope. They were possibly directed against the epitopes within the surface gene, such as d/y or w/r subtype determinants [31] .
Two of the characteristics of the a determinant mutations observed in the present study were that they occurred preferentially at the first loop (94%) and that position 126 of the first loop was affected most frequently (33%). In contrast, originally described vaccine-induced escape mutations involved the glycine r arginine mutation at position 145, which is located in the second loop of the a determinant [6] . In subsequent studies, a high proportion of escape mutations induced by vaccination or hyperimmune globulin therapy were also located in the second loop, position 145 being the hottest position [7, [10] [11] [12] . These observations in immunization recipients are consistent with the report that most anti-HBs in sera from vaccinees are targeted to an epitope between amino acids 139 and 147 [36] . In the present study, a glycine r arginine mutation at position 145 was observed in only 1 patient. These differences in the location of mutations may represent the distinctive feature of naturally occurring mutations and may suggest the differences in the target epitopes between naturally acquired anti- itope could lead to epitope inactivation and T cell receptor antagonism [37] . In fact, several studies have shown that patients with chronic active hepatitis often carry missense mutations or deletions in the middle of the core region of HBV, whereas mutations are not observed among patients with inactive disease, suggesting that these mutations in the core region may be CTL escape mutations [38] [39] [40] [41] . A previous study from Taiwan revealed a high frequency of mutations at positions 40 and 47 of the surface gene, which coincide with mouse H-2 L d -restricted and HLA A2-restricted CTL epitopes, respectively, and the authors suggested that these mutations could alter CTL recognition and predispose these patients to chronic infection. In the present study, however, mutations at amino acid residues 40 and 47 were observed in only 1 (2%) and 2 (5%) patients, respectively, and the other putative CTL epitopes were also conserved. Therefore, we could not confirm similar frequent mutations in the CTL epitopes of the surface gene. Because mutations at position 40 were preferentially seen in the HBV adw subtype (genotype B) in the study from Taiwan, they may be specific to genotype B, and thus we did not observe them in our study. However, the reason for the lack of frequent mutations at position 47 is not clear.
In the analysis of the overlapping polymerase gene, mutations at only 5 amino acid positions were observed in 11 patient. About half of these polymerase mutations simultaneously had mutations in the overlapping a determinant region of the surface gene, suggesting that they were probably affected by the primary mutations in the a determinant. The rest of the polymerase mutations, namely, at positions 423, 471, and 487, were not accompanied by the surface gene mutation and may have been primary mutations selected by undetermined selective pressures on the polymerase gene. Position 423 was located in the first amino acid position of the catalytic domain A, but this position seemed variable, according to the comparative study of the known RNA-dependent DNA polymerases [30] . The other mutations were outside of the 5 conserved catalytic domains of the polymerase gene and thus did not appear to affect the critical regions of the polymerase gene. In fact, the presence of these mutations was not associated with various clinical features, including serum HBV-DNA polymerase levels, HBV-DNA levels, ALT levels, and the presence of HBeAg, anti-HBe, or anti-HBs, suggesting that these mutations may not alter replication competency of the virus. The characterization of the functional significance of these mutations would require further in vitro studies. Mutations at several amino acid positions in the polymerase gene are reported to exert resistance to lamivudine or famciclovir therapy: phenylalanine r leucine in position 514, valine r leucine in 521, proline r leucine in 525, and leucine r methionine in 528 of the catalytic domain B [17, 18] and methionine r valine or methionine r isoleucine in position 552 in domain C, affecting the YMDD motif [17] . None of these mutations were observed in the present study. Therefore, naturally occurring mutations in the polymerase gene that could alter susceptibility to antivirus therapy seemed to be absent in those who have not received antivirus nucleoside analogues.
In conclusion, we have shown that the prevalence of naturally occurring mutations in the a determinant was unexpectedly high in patients with chronic hepatitis B. A high proportion of these natural mutations, unlike escape mutations induced by vaccine or immunoglobulin therapy, occurred in the first loop. These mutations were significantly associated with the presence of anti-HBs, suggesting that they may cause escape from the neutralizing antibody, thus contributing to persistent infection in some patients. In contrast, escape mutations in the putative CTL epitopes seemed rare, and natural mutations affecting the major catalytic domains of the polymerase gene that could alter susceptibility to therapy with antivirus nucleoside analogues were not observed at all.
